COSCIENS Biopharma Inc. (CSCI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, COSCIENS Biopharma Inc. (CSCI) has a cash flow conversion efficiency ratio of -0.627x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.45 Million) by net assets ($7.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see COSCIENS Biopharma Inc. stock valuation for the company's overall valuation and market capitalisation.
COSCIENS Biopharma Inc. - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how COSCIENS Biopharma Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View COSCIENS Biopharma Inc. (CSCI) stock price for real-time trading data and today's change.
COSCIENS Biopharma Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of COSCIENS Biopharma Inc. ranked by their cash flow conversion efficiency. Review how much free cash does COSCIENS Biopharma Inc. generate to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Green Earth Group N.V.
AS:HWK
|
0.038x |
|
Ebang International Holdings
NASDAQ:EBON
|
-0.038x |
|
Erria A/S
CO:ERRIA
|
0.381x |
|
Suzhou Goldengreen Technologies Ltd
SHE:002808
|
-0.049x |
|
Orient Press Limited
NSE:ORIENTLTD
|
0.114x |
|
Cerberus Cyber Sentinel Corp
NASDAQ:CISO
|
-0.006x |
|
HEBEI YICHEN GRP H YC 05
F:HE2
|
N/A |
|
W.A.G payment solutions plc
LSE:EWG
|
0.376x |
Annual Cash Flow Conversion Efficiency for COSCIENS Biopharma Inc. (1996–2024)
The table below shows the annual cash flow conversion efficiency of COSCIENS Biopharma Inc. from 1996 to 2024. Also see CSCI total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.16 Million | $-14.57 Million | -1.107x | -801.77% |
| 2023-12-31 | $21.04 Million | $-2.58 Million | -0.123x | -155.85% |
| 2022-12-31 | $23.79 Million | $5.23 Million | 0.220x | +73.55% |
| 2021-12-31 | $21.74 Million | $2.75 Million | 0.127x | -30.86% |
| 2020-12-31 | $19.06 Million | $3.49 Million | 0.183x | +363.33% |
| 2019-12-31 | $17.08 Million | $675.29K | 0.040x | +143.25% |
| 2018-12-31 | $17.04 Million | $-1.56 Million | -0.091x | -231.01% |
| 2017-12-31 | $17.93 Million | $1.25 Million | 0.070x | -68.00% |
| 2016-12-31 | $16.67 Million | $3.63 Million | 0.218x | -56.87% |
| 2015-12-31 | $5.68 Million | $2.87 Million | 0.506x | -50.46% |
| 2014-12-31 | $1.80 Million | $1.84 Million | 1.021x | -49.08% |
| 2013-12-31 | $229.62K | $460.21K | 2.004x | +123.19% |
| 2012-12-31 | $13.63K | $-117.82K | -8.642x | -653.59% |
| 2011-12-31 | $507.11K | $791.62K | 1.561x | +313.21% |
| 2010-12-31 | $-654.90K | $479.50K | -0.732x | -203.72% |
| 2009-12-31 | $-1.31 Million | $-925.47K | 0.706x | +23.17% |
| 2008-12-31 | $-1.59 Million | $-909.41K | 0.573x | +181.97% |
| 2007-12-31 | $1.57 Million | $-1.10 Million | -0.699x | -229.62% |
| 2006-12-31 | $260.64K | $140.59K | 0.539x | +158.09% |
| 2005-12-31 | $397.23K | $-368.84K | -0.929x | -14.94% |
| 2004-12-31 | $94.89K | $-76.65K | -0.808x | -537.56% |
| 2003-12-31 | $294.75K | $54.42K | 0.185x | +32.60% |
| 2002-12-31 | $-414.76K | $-57.75K | 0.139x | -78.26% |
| 2001-12-31 | $-714.40K | $-457.45K | 0.640x | +101.61% |
| 2000-12-31 | $-1.59 Million | $-506.44K | 0.318x | +101.16% |
| 1999-12-31 | $-1.31 Million | $-207.14K | 0.158x | -93.05% |
| 1998-12-31 | $-714.89K | $-1.62 Million | 2.273x | +574.75% |
| 1997-12-31 | $6.57 Million | $-3.14 Million | -0.479x | -101.57% |
| 1996-12-31 | $5.84 Million | $-1.39 Million | -0.237x | -- |
About COSCIENS Biopharma Inc.
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Colombia, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a chewable for cholesterol reducti… Read more